TG Therapeutics slips 3% as traders de-risk into May 4 earnings amid oil-driven risk-off
TG Therapeutics (TGTX) is slipping about 3% on April 27, 2026, with no new company press release or SEC filing pointing to a specific negative catalyst. The move looks tied to pre-earnings positioning ahead of the May 4, 2026 Q1 report and a broader risk-off tape driven by an oil spike tied to heightened Strait of Hormuz tensions.
1. What’s moving the stock
Shares of TG Therapeutics (TGTX) are down about 3% in Monday trading (April 27, 2026) without a clear, single-stock headline. A scan of recent company communications shows the most recent investor-facing update centered on upcoming multiple-sclerosis data presentations for BRIUMVI, not an adverse event, regulatory action, or guidance cut. (stocktitan.net)
2. The likely driver: pre-earnings de-risking plus a risk-off backdrop
With the next major scheduled catalyst being TG Therapeutics’ Q1 2026 earnings on Monday, May 4, 2026 (before market open, with an 8:30 a.m. ET call), some investors appear to be trimming exposure after the stock’s recent run-up. The broader tape also looks less supportive today as crude oil is jumping and markets are reacting to increased geopolitical tension around the Strait of Hormuz, which can pressure higher-beta groups like biotech. (marketbeat.com)
3. Key context investors are weighing into the next report
Earlier in 2026, TG Therapeutics highlighted strong 2025 BRIUMVI-driven revenue and issued 2026 total global revenue guidance of roughly $875–$900 million, setting a high bar for continued execution and demand capture. That backdrop can amplify near-term volatility into quarterly prints as investors debate whether uptake, gross-to-net dynamics, and operating leverage can keep pace with expectations. (ir.tgtherapeutics.com)